Navigation Links
Genoptix Announces Participation at Lazard Capital Management 6th Annual Healthcare Conference
Date:11/10/2009

CARLSBAD, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the Lazard Capital Management 6th Annual Healthcare Conference at The St. Regis Hotel in New York City on November 17-18, 2009.

Genoptix's EVP and CFO, Doug Schuling, will present at the conference on Tuesday, November 17, 2009 beginning at approximately 11:25 a.m. EST. He will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance.

The presentation is expected to last approximately 30 minutes, including a Q&A session, which will be web cast live and made accessible through the "Investors" section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. A replay will also be available for 30 days following the initial presentation web cast.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For mor
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genoptix Reports Strong Financial Results For Third Quarter 2007
2. Genoptix Announces Participation at the UBS Global Life Sciences Conference
3. Genoptix Announces Participation at the BIOCOM Investor Conference 2008
4. Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 500
5. Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
6. Genoptix Announces Participation at the 2009 Southern California Investor Conference
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... unique, Rice University-based program that combines a traditional ... undergraduate research internship in nanotechnology, has been awarded ... Heiskell Award for Innovation in International Education. , ... and honor the most outstanding initiatives in international ...
... January 28 Nycomed has granted,Sepracor, Inc. ... marketing and,commercialisation rights for Ciclesonide in the ... a novel principle of action. It,is the ... for the,treatment of asthma and in the ...
... Joseph F. Finn, Jr.,CPA, the Assignee for the Benefit ... of the Company,s fixed assets for in,excess of $300,000 ... to,the high volume of requests for due diligence materials ... the Company has,created an online datasite that allows access ...
Cached Biology Technology:Rice wins innovation award for international program 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 3Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 4Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 6
(Date:4/17/2014)... to treat tuberculosis could be the basis for a ... fungal infections and parasites, yet evade resistance, according to ... , Led by U. of I. chemistry professor Eric ... SQ109 attacks the tuberculosis bacterium, how the drug can ... malaria and how targeting multiple pathways reduces the ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... per eight hundred births, Down syndrome - or trisomy ... intellectual disability. It results from a chromosomal abnormality where ... chromosome 21 (1% of the human genome). A study ... Department of Genetic Medicine and Development at the University ... Nature , shed light on how the extra chromosome ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... The common fruit fly circling your week-old peach has ... the insect,s eggshell formation. The paradoxical finding gives ... eggshell layer forms as it points to a likely ... biologist in the Medical College of Georgia Schools of ...
... plain with the odd hydrothermal vent, the seafloor appears ... paper being published May 29 in Nature. A ... mid-ocean ridge spreading system, representing potentially the largest surface ... geomicrobiologist Katrina Edwards, the studys corresponding author. While ...
... WEST LAFAYETTE, Ind. - Throughout the overlooked depths of ... important animal is rapidly disappearing. Until recently, the ... was a major food source for commercially important species ... salmon, trout and walleye rely. Scientists are employing ...
Cached Biology News:Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 2Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 3'Barren' seafloor teeming with microbial life 2'Barren' seafloor teeming with microbial life 3A Great Lakes mystery: The case of the disappearing species 2A Great Lakes mystery: The case of the disappearing species 3A Great Lakes mystery: The case of the disappearing species 4
... (CMV) pp65 Antigenemia Immunofluorescence Assay (IFA) is ... matrix protein pp65 of CMV in isolated ... Erythrocyte Lysis Buffer - ... mL of buffered ammonium chloride. (NH4CL) ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... both 0.2 and 2.0 mL samples for freezing point determinations. Includes built-in ... reading capability with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: